Evaluation of dual pathogen recognition receptor agonists as adjuvants for respiratory syncytial virus - virus-like particles for pulmonary delivery
The lack of pathology, combined with the robust mucosal and systemic immune responses, suggests that pulmonary delivery of adjuvanted RSV-VLPs may provide effective protection without the risk of vaccine-enhanced disease. The study also demonstrates that the chimeric TLR2/TLR7 agonist CL413 is a promising adjuvant for RSV-VLPs to induce mucosal and systemic immune response and warrant further investigations in more advanced preclinical models.
Authors
- Vidya A. Arankalle (ORCID: https://orcid.org/0000-0002-9940-3437)
- Anke Huckriede (ORCID: https://orcid.org/0000-0002-2646-5143)
- Harshad P. Patil (ORCID: https://orcid.org/0000-0002-2345-9266)
- Ahmedali S. Mandviwala (ORCID: https://orcid.org/0009-0009-8553-1911)
- Komal Liman
Institutions
- University Medical Center Groningen (NL)
- University of Groningen (NL)
- Bharati Vidyapeeth (Deemed to be University) (IN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-03-17
- DOI
- https://doi.org/10.3389/fimmu.2025.1561297
- Citations
- 2
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 2.71
Funders
- The Wellcome Trust DBT India Alliance